Maya Chen: Hey, you ready — I feel like I've been sitting with this one all morning and I need to talk it out.
Jonathan Ingles: I had a doctor's appointment yesterday, routine stuff, and they handed me this printout — 'biological age: 41.' I'm 39. And I just stared at it. Like, okay, so what do I do with that number?
Maya Chen: That's — yeah, that's exactly the itch. Because the number exists, and it feels meaningful, and then you walk out and... nothing changes.
Jonathan Ingles: Which brings us to this. Everyone keeps saying intrinsic capacity asks a different question than biological age. So tell me what that question actually is — plain terms, no WHO policy language.
Maya Chen: Okay, so — biological age is like popping the hood and checking the engine parts for wear. The gaskets look like a 41-year-old's gaskets, fine. Intrinsic capacity asks: can the car actually get you where you need to go today? Can you climb stairs, remember where you parked, hear your name called across a room?
Jonathan Ingles: Fine. But the WHO built ICOPE around five separate domains to answer that. Locomotion, cognition, vitality, psychological health, sensory function. Why does it take five domains to answer what sounds like one question?
Maya Chen: Because the car can fail in five different ways — and they don't all fail together. That's sort of the whole point. A Lancet Healthy Longevity study tracked 746 older adults through the final twenty years of their lives, and IC dropped from roughly 80 down to 47 on a hundred-point scale. But the decline wasn't uniform across domains. That's what a single biological-age number completely hides.
Jonathan Ingles: Wait — all 746 of those people were deceased by the time the data was analyzed?
Maya Chen: All of them — every single person in the Precipitating Events Project cohort, all 746, deceased by November 2024. Which is — I mean, that's what makes the 47 to 48 percent lower disability odds per ten-point IC score so striking, and also sort of... wait, actually it's what makes it complicated. Because you're looking backward through the end of people's lives.
Jonathan Ingles: That's not a footnote. That's the whole structure of the finding.
Maya Chen: No, you're right, it's not. The cohort is entirely decedents. So what the study actually measured — the 80-point start dropping to 47 over twenty years — that's what IC decline looks like for people who lived to be 70-plus AND stayed in the study. The person whose IC collapsed at 64 and died? Not in there.
Jonathan Ingles: So aren't we just measuring what predicted function among people who were already, in some sense, the survivors?
Maya Chen: Yeah, and the investigators actually — they flag this themselves. They describe the research on IC assessment and intervention as still in its infancy. Which is a remarkable thing to say about a number you're handing someone in a clinic.
Jonathan Ingles: Infancy. Their word.
Maya Chen: Their word. And look — picture someone, say, an 81-year-old man, sitting at a follow-up appointment. His IC score dropped nine points in a year. Locomotion is the domain that slid. The clinician hands him that breakdown and says 'your walking speed and chair-stand score fell.' That specificity is real. But whether acting on that number — versus just being told 'do more resistance training' — actually changes what he does on Tuesday morning? That trial doesn't fully exist yet.
Jonathan Ingles: And the WHO built ICOPE for low-resource community screening — not for a single 81-year-old in a premium clinic parsing domain breakdowns.
Maya Chen: Which is maybe the tension worth sitting with — the number is real, the survivor-bias caveat is real, and the intervention evidence is, by the field's own admission, not there yet.
Jonathan Ingles: And that 'infancy' admission is exactly where the actionability claim falls apart. Look — the 73-year-old woman gets her IC score back. Fifty-two out of a hundred. Vitality at 41, locomotion at 68. The clinician says vitality is the priority. The prescription: resistance training, more protein, more walking. How is that different from what her GP said five years ago?
Maya Chen: The targeting is — I mean, it's more specific than 'eat better and move more,' which is what she's been hearing, right? The IC breakdown tells her it's the vitality domain specifically, which maps to grip strength and nutritional status, not her cognition, not her — wait, actually, the uncomfortable part is that the intervention still sounds identical.
Jonathan Ingles: Exactly. Show me the trial. Not the theory — the actual head-to-head. Does domain-specific IC feedback produce different behavior than a biological-age score? Because that trial doesn't exist.
Maya Chen: No robust head-to-head, no. That's — yeah, that's accurate.
Jonathan Ingles: And the window is closing on IC's claimed edge anyway. Proteomic clocks, speech-based aging clocks — an NIH-covered speech clock that reads accelerated aging from how you talk — those are getting domain-specific too. If the competition catches up on specificity, what does IC actually have left?
Maya Chen: Honestly? The functional grounding, maybe. A speech-based clock tells you your cells are aging faster. IC's locomotion domain tells you your chair-stand score dropped — that's something you feel in your body, not just a molecular readout divorced from your life. There's a difference between cellular age and what you can actually do on a Tuesday morning.
Jonathan Ingles: I'll grant it.
Maya Chen: Though — and this is the part we should come back to — the WHO built all of this for community screening in low-resource settings, and what it's actually becoming in places like Northwestern's five-thousand-five-hundred-dollar-a-year clinic is something very different. That gap is where things get really uncomfortable.
Jonathan Ingles: Frankly, that's the sharper question. Who actually benefits from this measurement?
Maya Chen: And that gap — between who it was built for and who's actually using it — that's what I keep thinking about. ICOPE was designed by the WHO as a community screening tool. Cheap, scalable, no fancy lab required. A health worker in a low-resource setting could run through the five domains with a stopwatch and a handgrip meter. That was the whole point.
Jonathan Ingles: And now it's sitting inside Northwestern's longevity clinic at fifty-five hundred dollars a year.
Maya Chen: Alongside VO2 max testing and — and this is the part that actually bothers me — alongside less-validated biological-age measures. Dr. Baljash Cheema, the cardiologist running that clinic, has actually spoken to this boundary, the line between what's validated and what isn't. But the IC framework gets bundled in with the unvalidated stuff, which sort of... wait, it almost launders the premium package. Like, the WHO credibility travels with the price tag.
Jonathan Ingles: That's the capture mechanism exactly. You take a public-health equity tool, attach it to a validated measure like VO2 max, surround it with speculative aging clocks, and the whole bundle reads as cutting-edge. Nobody separates them at the checkout.
Maya Chen: Right — but the part that doesn't fit neatly is that IC does something in that clinic that the biological-age clocks genuinely don't. The healthspan framing — years lived with functional ability, not just years lived — that's a real clinical shift. Even at Northwestern, even at fifty-five hundred dollars.
Jonathan Ingles: I'll grant the healthspan distinction. Lifespan tells you when the car stops. IC tells you whether you could drive it last Tuesday.
Maya Chen: But imagine — a community health worker in a rural clinic, no epigenetic sequencer, no VO2 treadmill, doing a chair-stand test in a church hall. That's who ICOPE was actually written for. That person never sees the Northwestern program. And the tool that was supposed to reach her is now most visible inside a premium package she'll never access.
Jonathan Ingles: The measurement doesn't fix the access problem. It just reflects it back at higher resolution.
Maya Chen: Yeah. And that might be the most honest thing we've said — the WHO built this to surface inequality, and what it's actually doing, at least in its most visible American form, is servicing it.
Jonathan Ingles: So the last question — and I don't think the data answers it, and I'm not sure the clinicians do either — is what would it actually take to measure the structural stuff? Not the downstream score. The upstream causes. Income, neighborhood walkability, whether someone lives alone. Those are the things that determine where IC lands. Why aren't we building that framework instead?
Maya Chen: I mean — I think about the WHO designing ICOPE for a health worker with a stopwatch in a church hall, and... that version of the tool was almost trying to do that. Surface who's been left without resources by measuring what their body shows for it. But the honest answer to your question is I don't know. I genuinely don't know why that's not the intervention.
Jonathan Ingles: That's probably the right place to stop. Not because it's resolved — it's not — but because that's the actual unanswered question sitting under all of it.
